Surgical oncologists perform a delicate balance, completing tumor resection while aiming to preserve healthy tissue and functionality.
In these delicate procedures, some cancer gets missed, and some are deemed unresectable due to important local anatomical features and structures.
Either way, patients left with residual cancer following surgery will generally have a poorer prognosis.
No one wants this outcome, and we believe it doesn’t need to be this way…
OncoLux’s new Optical Theranostic system combines intraoperative enhanced visualization of residual cancer with optical photodynamic therapy, allowing surgeons to